Chen P F, Freedman R S, Chernajovsky Y, Platsoucas C D
Department of Immunology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Hum Antibodies Hybridomas. 1994;5(3-4):131-42.
We have employed conventional polymerase chain reaction (PCR) and nonpalindromic adaptor PCR (NPA-PCR) for the amplification of the heavy- and light-chain transcripts of the cDNAs of two human monoclonal antibodies (MAb), designated AC6C3 (IgM, lambda) and CR4E8 (IgM, lambda), recognizing two different antigens expressed on the cell surface of human ovarian, cervix, breast, colon, melanoma and other carcinomas. With few exceptions these MAbs do not react with normal tissues. The AC6C3 MAb was developed by fusing regional lymph node lymphocytes from a patient with ovarian carcinoma with cells of the hybrid myeloma line SPAZ4, whereas the CR4E8 MAb was developed by fusing SPAZ4 cells with peripheral blood lymphocytes from a patient with cervical cancer, who was immunized intralymphatically with a viral oncolysate allogeneic tumor vaccine. The AC6C3 MAb immunoprecipitated from lysates of the ovarian tumor cell line SKOV3 a 32 kD polypeptide. The CR4E8 MAb reacted in Western blotting of lysates of the SW756 cervical carcinoma line with a 55 kD band. Cell surface immunofluorescence determinations using the fluorescence activated cell sorter revealed that both MAbs stain ovarian or cervix carcinoma tumor cell lines. We amplified the heavy chain transcripts of these two MAbs by conventional PCR, using mixed 5' end amplification primers, corresponding to the most conserved VH leader sequences and a C mu probe as a 3' end amplification primer. However, the mixed primer approach did not permit the amplification of the lambda-chain transcripts of these two human MAbs. This amplification was successfully carried out using the NPA-PCR that we have previously developed, specifically for the amplification of transcripts with unknown or variable 5' end, such as the T-cell receptors and the immunoglobulins. We have cloned and sequenced the amplified cDNAs. Sequence analysis showed that the V lambda segment of the AC6C3 MAb had 80.29% homology to the human germline Ig lambda-chain V lambda III.1, clone DPL2. The V lambda region of the CR4E8 MAb had 99.28% homology also to the human germline Ig lambda-chain, V lambda III.1, clone DPL23. The AC6C3 MAb lambda-chain employed a J segment with 98% homology to J3. The CR4E8 MAb light chain employed the J(H6-3C4) gene segment. Both MAbs utilized identical VH and JH gene segments and different DH segments. The VH regions of the AC6C3 MAb and of the CR4E8 MAb had, respectively, 98.6% and 98.98% homology to the human Ig germline heavy chain V region DP-7, a member of the VH-1 gene family.(ABSTRACT TRUNCATED AT 400 WORDS)
我们采用常规聚合酶链反应(PCR)和非回文衔接子PCR(NPA-PCR)来扩增两种人单克隆抗体(MAb)cDNA的重链和轻链转录本,这两种单克隆抗体分别命名为AC6C3(IgM,λ)和CR4E8(IgM,λ),它们可识别在人卵巢癌、宫颈癌、乳腺癌、结肠癌、黑色素瘤及其他癌的细胞表面表达的两种不同抗原。除少数例外情况,这些单克隆抗体与正常组织不发生反应。AC6C3单克隆抗体是通过将一名卵巢癌患者的区域淋巴结淋巴细胞与杂交骨髓瘤细胞系SPAZ4的细胞融合而产生的,而CR4E8单克隆抗体是通过将SPAZ4细胞与一名宫颈癌患者的外周血淋巴细胞融合产生的,该宫颈癌患者经淋巴管内注射异体肿瘤溶瘤病毒疫苗进行免疫。AC6C3单克隆抗体从卵巢肿瘤细胞系SKOV3的裂解物中免疫沉淀出一种32 kD的多肽。CR4E8单克隆抗体在SW756宫颈癌细胞系裂解物的蛋白质印迹分析中与一条55 kD的条带发生反应。使用荧光激活细胞分选仪进行的细胞表面免疫荧光测定显示,这两种单克隆抗体均可对卵巢癌或宫颈癌细胞系进行染色。我们使用常规PCR扩增这两种单克隆抗体的重链转录本,使用混合的5'端扩增引物,其对应于最保守的VH前导序列,并使用Cμ探针作为3'端扩增引物。然而,混合引物方法无法扩增这两种人单克隆抗体的λ链转录本。使用我们之前开发的NPA-PCR成功进行了这种扩增,该方法专门用于扩增5'端未知或可变的转录本,如T细胞受体和免疫球蛋白。我们对扩增的cDNA进行了克隆和测序。序列分析表明,AC6C3单克隆抗体的Vλ区段与人种系Igλ链VλIII.1、克隆DPL2具有80.29%的同源性。CR4E8单克隆抗体的Vλ区域与人种系Igλ链VλIII.1、克隆DPL23也具有99.28%的同源性。AC6C3单克隆抗体的λ链使用了与J3具有98%同源性的J区段。CR4E8单克隆抗体的轻链使用了J(H6-3C4)基因区段。两种单克隆抗体均使用相同的VH和JH基因区段以及不同的DH区段。AC6C3单克隆抗体和CR4E8单克隆抗体的VH区域与人Ig种系重链V区域DP-7(VH-1基因家族的成员)分别具有98.6%和98.98%的同源性。(摘要截短至400字)